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Differing roles of CD18 and VLA-4 in leukocyte migration/activation
during anti-GEM nephritis. The mechanisms underlying leukocyte migra-
tion into inflamed glomeruli and their in situ activation are incompletely
understood. We addressed this issue by investigating the effects of
monoclonal antibodies (mAbs) to CD18 and VLA-4 on these process in
the heterologous phase of anti-glomerular basement membrane (GBM)
nephritis in rat. Anti-CD 18 mAb substantially attenuated neutrophil
(PMN) migration into glomeruli and the accompanying proteinuria which
is a function of in Situ leukocyte activation (ca. 60%). Anti-VLA-4 mAb
modestly inhibited PMN migration (Ca. 20%) and had no significant effect
on proteinuria. Combination of both mAbs was no more effective than
anti-CD18 mAb alone. Despite continued mAb blockade of CD18 or
VLA-4 (or both), macrophage (M4) migration following PMN influx was
unaltered. However, combined CDI8/VLA-4 mAbs diminished the pro-
teinuria associated with M4 influx (ca. 50%). Abrogation of the acute
influx of PMNs in this model (via complement depletion or anti-PMN
antibody) did not diminish the following influx of M4s, although the
associated proteinuria was abolished. In this context, M migration was
substantially decreased by anti-VLA-4 mAb (Ca. 50%), but not anti-CD18
mAb (either alone or with anti-VLA-4 mAb). In sum, leukocyte migration
and activation in the heterologous phase of anti-GBM nephritis are
dependent on CD18 and VLA-4, although to vaiying degrees depending
on the leukocyte subtype and the presence of prior inflammation. None-
theless, a significant component of both PMN and Mçb migration/activa-
tion is CDI8/VLA-4 independent.
Leukocytes are critical effectors of glomerular damage in the
context of immune-mediated glomerulonephritis. They can in-
duce directly acute glomerular dysfunction via their elaboration of
reactive oxygen species and proteases, influence the evolution of
the inflammatory process via their elaboration of cytokines, and
ultimately play an important role in determining whether acute
glomerular injury resolves or produces glomeruloscierosis [1—4].
Given their pivotal nature as effectors of glomerular injury and
scarring, understanding the mechanisms underlying their influx
into the inflamed glomerulus is critically important.
The influx of leukocytes into a focus of inflammation and in situ
activation are both a complex function of cytokines, chemokines
and adhesion molecules [5, 6]. With respect to adhesion mole-
cules, it has become apparent from in vitro and in vivo data that
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CD18 and VLA-4 are the principal leukocyte adhesion molecules
which regulate the adherence and migration of neutrophils
(PMNs) and macrophages (M4s) during inflammation, although
the contribution of these adhesion molecules may vary consider-
ably as a function of the tissue and inflammatory stimulus [7—15].
Apropos to this issue, a number of recent studies have explored
the role of leukocyte adhesion molecules in mediating the influx
and in situ activation of leukocytes in anti-glomerular basement
membrane (GBM) nephritis although not with entirely consonant
results. Two recent studies found that CDI8 is the predominant
leukocyte adhesion molecule which mediates the influx of PMNs
into the glomerulus and their in situ activation [16, 17], although
another recent study failed to discern a role for CDI8 [18]. In
addition, recent data suggest that VLA-4 (CD49d/CD29) partic-
ipates in the acute influx of PMNs in anti-GBM nephritis [17],
although the relative contribution of this adhesion molecule is
uncertain.
Little is known about the leukocyte adhesion molecules under-
lying the influx of Ms into the glomerulus in the context of
anti-GBM nephritis, although it has been clear for some time that
the influx/activation of PMNs and M4s are not obligatorily linked
processes [19, 20]. Recent studies have suggested that CD11a/
CD18 is necessary for the migration of monocytes into the
glomerulus and chronic glomerular injury [21, 22]. These studies,
however, contrast with other studies of inflammation which have
found that CDl8perse mediates only a small portion of monocyte
migration, and that VLA-4 provides a critical CD18-independent
pathway of monocyte adhesion and migration [7—13].
To address these uncertainties, we examined the independent
and combined roles of CD18 and VLA-4 in the migration of
leukocytes (both PMNs and monocytes/Ms) into the glomcrulus
during the heterologous phase of anti-GBM nephritis using in vivo
monoclonal (mAb) blockade of these adhesion molecules, Be-
cause migration and in situ activation are separable phenomena
[16, 23], we additionally sought to determine the role of these
adhesion receptors in the activation of glomerular leukocytes as
manifested by proteinuria. Our prima facie hypothesis was that
both integrins would be important for leukocyte migration/activa-
tion, although their relative importance would differ for PMNs
and monocytes. Although the data we derived in the current work
support this hypothesis, they also suggest that a substantial
component of leukocyte migration/activation is CD18/VLA-4-
independent in this model.
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Fig. 1. Characterization of anti-CDJ8 mAb 6G2. Mab 6G2 was derived
from a Balb/c mouse immunized with rat M4s and characterized by
immunoprecipitation, FACS and adhesion bioassay as detailed in the
Methods section. A. Immunoprecipitation of surface-labeled rat PMNs
by 6G2, 0X42 (anti-CD11b) and 0X42 after immunoprecipitation by
6G2 (6G210X42). B. FACS analysis of PMNs, alveolar M4s and
thymocytes with 6G2. C. Effects of 6G2 on the adhesion of alveolar
M4s to GBM in vitro.
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Fig. 2. Effect of anti-CDI8 and -VLA-4 mAbs on circulating leukocytes.
Peripheral leukocyte counts and differential analysis were performed on
animals injected with either anti-CD18 (S total; • PMN5) or anti-VLA-4
(0 total; LI PMN5) mAb (1 mg i.v.) at selected time points. N = 3 for all
groups. Circulating leukocytes were elevated at 24 and 48 hours with
anti-CDI8 mAb treatment, and at all time points with anti-VLA-4 mAb
treatment (P < 0.05). PMN counts were elevated at 48 hours in anti-CD18
and at 48 and 72 hours in anti-VLA-4 mAb treated animals (P < 0.05).
-
Fig. 3. In vivo suiface saturation of circulating leukocytes after injection of
anti-CDJ8 ,nAb. FACS analysis of peripheral leukocytes was performed at
varying time points after the injection of anti-CD18 mAb, 602, as detailed
in the Methods section. Solid lines represent labeling in vivo (no primary
antibody added in vitro), while dotted lines represent labeling after
exposure to 6G2 in vitro. Dashed lines show labeling of leukocytes by
CD45.
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Methods
Production, characterization and in vivo validation of mAbs to rat
CD18 and VLA-4
A mAb of rat CD18 was produced for these studies by
immunizing Balb/c mice with rat alveolar M4s (Lewis strain,
Charles River, Wilmington, MA, USA). The spleen from a mouse
with high titer anti-M4 reactivity in serum (as determined by
immunocytochemisty [16]) was then fused with SP2/0 myeloma
cells in the Washington University Hybridoma Center. The result-
ing clones were then screened for the ability to inhibit M4
adherence and spreading on GBM coated-plastic 96 well ELISA
plates (Costar, Cambridge, MA, USA). GBM was isolated as
published [24]. The clone which was most active in this assay, 602,
was then further characterized by immunoprecipitation, immuno-
fluorescent staining of leukocytes, and functional assays. Isotype
characterization (using a kit from BioRad, Hercules, CA, USA)
showed this mAb to be an IgGi.
For immunoprecipitation, PMNs (isolated by peritoneal lavage
from rats injected i.p. with 1% glycogen in PBS) were suspended
in 0.15 M NaC1, 0.1 M HEPES pH 8.0 containing 1 mglml of
NHS-LC biotin (Pierce, Rockford, IL, USA). After one hour at
room temperature, the cells were washed and then lysed in 150
mM NaCl, 50 mr't Tris, 1 mivi EDTA, 1% Triton X-100 with
protease inhibitors (iodoacetamide 10 mrvi, leupeptin 10 tgIml,
aprotinin 10 j.g/ml, PMSF 1 mM; Sigma, St. Louis, MO, USA).
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After preclearing, the lysate was immunoprecipitated using 6G2
or 0X42 (anti-CD11b mAb [25, 26]), either alone or after 6G2
and agarose anti-mouse lgG (Sigma). Labeled proteins were
resolved by SDS-PAGE (7.5% gel) followed by transblotting.
Blots were blocked with 10% milk in PBS-0.1% Tween, incubated
with avidin-peroxidase (Sigma) diluted 1:1000 vol/vol in PBS-
0.1% Tween, and biotin-labeled proteins visualized by chemilu-
minescence (ECL system; Amersham, Buckinghamshire, UK).
FACS analysis was performed as previously described using a
rabbit anti-mouse IgG-FITC conjugate (Sigma) employing a
FACScan (Becton Dickinson, Mountain View, CA, USA). Alve-
olar M4s, elicited PMNs and thymocytes were used for FACS
characterization. Functional assays used for characterization were
adherence to plastic [27] and homologous aggregation of thymo-
cytes [28], due to CD11b/CD18 and CDI la/CDI8, respectively.
The mAb 6G2 was partially purified prior to use in vivo. Ascites
containing 6G2 was treated with caprylic acid and the resulting
supernatant filtered through a Centricon 100 (Amicon, Beverly,
MA, USA). Antibody was then suspended in sterile 0.9% NaCl,
sterile filtered, and stored at —20°C prior to use at 1 mg/mI.
Endotoxin content of this antibody was < 200 pg/ml.
48 hr Development and characterization of the mAb to rat VLA-4,
TA-2, have been published previously [29]. This mAb is an IgGi
that recognizes the CD49d subunit and is function-blocking. TA-2
was used as sterile ascites diluted to an antibody content of 2
mg/ml. As a control for mAb administration, B9, an IgGi mAb to
pertussis toxin, was given to a group of nephritic animals (also as
sterile ascites diluted to 2 mg/mI) [30]. Administration of the
control mAb, B9, did not alter the leukocyte influx or proteinuria
in anti-GBM nephritis (data not shown). In consequence, data
from B9-treated and untreated controls were combined.
MAbs were administered to animals by intravenous injection.
In order to validate efficacy of adhesion receptor blockade,
coating of circulating leukocytes by antibody was determined at 0,
24, 48, and 72 hours after injection of mAb by flow cytometry
using previously detailed methods [16]. In brief, peripheral leu-
kocytes were isolated from heparinized blood which was adjusted
to 1% dextran by sedimentation at 1 g for one hour at 25°C.
Leukocytes were then labeled with a rabbit anti-mouse IgG
F(ab')-FITC conjugate (Sigma) directly to assess the number of
cells labeled with the mAb in vivo. Alternatively, leukocytes were
exposed to the same mAb as that injected intravenously prior to
labeling to assess the total number of cells expressing the relevant
adhesion receptor. Comparison of these two curves was used to
determine the efficiency of in vivo adhesion receptor blockade. As
a control and to aid in gating, peripheral leukocytes were also
labeled for CD45 using OX1 (Chemicon, Temecula, CA, USA).
Labeled cells were quantified on a FACScan as above. In parallel
experiments, circulating leukocyte counts and differential analysis
were performed by hemocytometer and by using Diff-Quick
stained blood films (Baxter, McGaw Park, IL, USA).
0 hr
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Fig. 4. In vivo surface saturation of circulating leukocytes after injection of
anti-VLA-4 mAb. FACS analysis of circulating leukocytes was performed
at varying time points after the injection of anti-VLA-4 mAb, TA-2, as
detailed in methods. Solid lines represent labeling in vivo, while dotted
lines represent labeling after exposure to TA-2 in vitro. Dashed lines show
labeling of leukocytes by CD45.
24 hr
.0
E
a)0
S
S
72 hr
100 101 102
Relative fluorescence
466 Wu et al: Role of CDI8 and VLA-4 in anti-GBM nephritis
Induction and manipulation of heterologous anti-GBM nephritis
Heterologous anti-GBM nephritis was induced in Lewis rats
(Charles River) by the intravenous injection of a rabbit polyclonal
antibody to rat GBM described previously [16]. This model of
nephritis is characterized by linear deposition of IgG and C3 in
the GBM, accompanied by an infiltrative/diffuse proliferative
nephritis with proteinuria lasting>72 hours [reviewed in 1,2]. To
assess proteinuria, urine was collected using a metabolic cage and
protein determined by the Bradford assay (Bio-Rad). To quantify
the influx of leukocytes into the glomerulus, glomeruli were
isolated from saline-perfused kidneys using a sieving protocol and
dispersed into a single cell preparation as previously described
[16]. Cells were centrifuged onto slides (Shandon Inc., Pittsburgh,
PA, USA), fixed with methanol/acetone (50:50 vol/vol), and
leukocytes were labeled with an anti-CD45 antibody (OX1) as
detailed [16]. Hematoxylin was used as a counterstain. The
labeled cells were quantified as a percentage of the total by light
microscopy and categorized by nuclear morphology as to lineage.
Total leukocyte content was calculated by multiplying percentages
by the cell yield per glomerulus. This method correlates well with
other methods of leukocyte quantification (staining tissue sec-
tions, in situ labeling of intact glomeruli) [31, 32].
To study the effect of mAbs on anti-GBM nephritis, rats were
treated with 1 mg of mAb (6G2, anti-CD18; TA-2, anti-VLA-4/
CD49d; or B9, control mAb) 30 minutes prior to induction of
disease and in some experiments 36 hours after disease induction.
To assess the effect on the early inflammatory phase, proteinuria
was determined by collecting urine from 0 to 24 hours after
disease induction and glomerular leukocytes quantified at three
hours after disease induction. To assess the effect on the later
inflammatory phase, proteinuria was determined by collecting
urine from 48 to 72 hours after disease induction and glomerular
leukocytes quantified at 72 hours.
To determine the effects of mAbs on M4 migration/activation
in the absence of acute inflammation, animals were either com-
plement- or PMN-depleted prior to induction of nephritis. Com-
plement depletion was effected using cobra venom factor (CVF)
as previously described (CVF; Diamedix, Miami, FL, USA) [33].
PMN depletion was accomplished using a rabbit anti-rat PMN
antibody (Accurate; Westbury, NY, USA) as published [23]. PMN
depletion was induced before the induction of disease by the
injection of anti-PMN antiserum (2.5 ml/kg). To determine the
effect of CD18 and VLA-4 blockade in these animals, mAbs were
administered 24 hours after disease induction.
Data analysis
FACS, immunoprecipitation, and adherence bioassay data are
presented as representative experiments (1 out of 3). Other data
are presented as the mean SEM of several independent experi-
ments with the appropriate N indicated in the Figure legends or
text. Because substantial interexperimental variability in protein-
uria was observed (in part due to the use of different batches of
anti-GBM antiserum), proteinuria is normalized to contempora-
neously performed controls for statistical comparison. Quantita-
tive data on proteinuria (averages and ranges), however, are also
presented in the text or Figure legends. Less variability in
glomerular leukocyte counts was observed (since experiments
were performed with a single batch of anti-GBM) and non-
normalized data are presented. Data were analyzed by ANOVA
Normals Acute Chronic
Fig. 5. Evolution of proteinuria and glomendar leukocyte counts during
acute and chronic phases of heterologous anti-GBM nephritis. Animals were
injected with anti-GBM antibody and proteinuria determined during the
acute (0 to 24 hr) and chronic phases (48 to 72 hr) of the disease model
(A). Glomeruli from nephritic animals were also removed during the acute
and chronic phases (3 and 72 hr, respectively) and glomerular leukocytes
quantified and subtyped by immunocytochemistiy as detailed in the
Methods Section (B). The data shown are the aggegate quantitative data
from the controls used in the experiments shown in Figures 6 to 9 (N = 8).
Data from normal animals are provided for comparison (N = 10). Symbols
are: () total; (i) PMNs; () M4s.
using Bonferroni's correction for multiple comparisons and sta-
tistical significance is indicated if P < 0.05.
Results
Characterization of 6G2 as an anti-CDI8 mAb
The mAb 6G2 was characterized as directed against CD18 by
immunoprecipitation, FACS and adherence bioassay. As shown in
Figure 1A, mAb 6G2 immunoprecipitated a dimer from PMNs
which comigrated with that immunoprecipitated by 0X42,
CD1 lb/CD18 (Fig. 1A). Preclearing lysates with 6G2 substantially
diminished the intensity of the bands immunoprecipitated by
OX42 indicating that 6G2 recognized CD1 lb/CD18 (Fig. 1A).
Variably, an additional band below the CD1Ib band was immu-
noprecipitated from PMNs with 6G2 (presumably CD1 ic, data
not shown). Both myeloid cells (PMNs, Ms) and lymphoid cells
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Fig. 6. Effect of mAbs to CD18 and VLA-4 on proteinuria from 0 to 24
hours after induction of anti-GBMnephritis. Proteinuria was measured over
the initial 24 hours of disease in nephritic animals (Neph.) and groups of
nephritic animals given anti-CD18 and/or anti-VLA-4 mAbs 30 minutes
prior to disease induction (csCDl8, aVLA-4, and csCDl8+VLA-4, respec-
tively). Proteinuria was normalized to contemporaneously performed
controls (= 100%). N = 8, 6, 3, and 5 in the groups shown. The decrease
in proteinuria in animals given anti-CD 18 mAb (alone or in combination
with anti-VLA-4) relative to control was statistically significant (P < 0.05).
Fig. 7. Effect of mAbs to CDJ8 and VLA-4 on glomerular leukocytes three
hours after induction of anti-GBM nephritis. Glomerular leukocytes were
measured by immunocytochemistry (Methods) three hours after induction
of nephritis in controls (Neph.), anti-CD18 niAb pretreated animals,
anti-VLA-4 mAb pretreated animals, and animals pretreated with combi-
nation therapy (aCD18, aVLA-4, and aCD18+VLA-4, respectively).
Total glomerular leukocytes (A) as well as PMN (B) and M4 (C) counts
are shown. N = 4, 4, 3, and 3, respectively, for the groups as shown.
Glomerular leukocytes were decreased significantly in anti-CD18 mAb
treated animals (alone or in combination, P < 0.05). There was a trend
towards significance for anti-VLA-4 treated animals (P = 0.09) For
PMN5, all three experimental groups were significantly decreased relative
to control (P < 0.01 for anti-CD18-treated animals, P < 0.05 for
anti-VLA-4 treated animals).
due to TA-2 (anti-VLA-4/CD49d) resulted more from an increase
in lymphocytes (Fig. 2). Combination blockade produced an
additive effect (data not shown). By FACS analysis, 6G2 both
down-regulated the expression of CD18 by peripheral leukocytes
and effectively saturated CD18 for ca. 48 hours (Fig. 3). The in
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(thymocytes) exhibited the antigen recognized by 602 (Fig. 1B),
whereas 0X42 labeled only myeloid cells ([25] and data not
shown). Also, as shown in Figure 1C, 6G2 was function-blocking
in that it inhibited M4 adherence to tissue culture plastic in vitro.
Homologous aggregation of thymocytes was also blocked with
6G2 (data not shown). On the basis of these results, we concluded
that 6G2 recognized CD18.
In vivo validation of mAb blockade of CDJ8 and VLA-4
The in vivo effect of the mAbs, 6G2 (anti-CD18) and TA-2
(anti-VLA-4/CD49d), on peripheral leukocyte counts and in vivo
saturation of leukocyte adhesion molecules was determined sub-
sequently. In vivo administration of either niAb alone (or both
mAbs together) produced a leukocytosis which lasted for > 48
hours for 6G2 (anti-CD18) and > 72 hours for TA-2 (anti-VLA-
4/CD49d) (Fig. 2). For 6G2 (anti-CD18), the leukocytosis was
predominantly due to an increase in PMNs, while the leukocytosis
Neph. aCD18 aVLA-4 aCD18+VLA-4
ra
0
0
C
ci)0
0.
ci)C
Neph. aCD18 aVLA-4 aCD18+VLA-4
Fig. 8. Effect of mAbs to CDJ8 and l/LA-4 on proteinuria from 48 to 72
hours after induction of anti-GBM nephritis. Proteinuria was measured in
nephritic animals (Neph.) and subgroups of nephritic animals given
anti-CD18 and/or anti-VLA-4 mAbs 30 minutes prior to, and 36 hours
after, disease induction (anti-CD18, anti-VLA-4, and anti-CD18+VLA-4,
respectively). Proteinuria was normalized to contemporaneously per-
formed controls (= 100%). N = 8, 6, 3, and 5, respectively, in the groups
shown. The decrease in proteinuria in animals given anti-CD18 and
anti-VLA-4 mAbs together relative to control was statistically significant
(P < 0.05).
vivo effects of TA-2 were similar except that the duration of
blockade was even more prolonged with effective saturation of
leukocyte VLA-4 observed up to 72 hours (Fig. 4),
Effects of anti-CD18 and anti- J/LA-4 mAbs on the early phase of
heterologous anti-GBM nephritis
The early phase of heterologous anti-GBM nephritis was
characterized by proteinuria which occurred concomitantly with
an influx of PMNs into the glomerulus (Fig. 5). We initially
determined the effects of mAb blockade of leukocyte adhesion
receptors on this phase of the disease model by pretreating
animals the aforementioned mAbs prior to disease induction.
Although there was variability in the acute proteirluria between
experiments, proteinuria in nephritic animals averaged 309 45
mg/24 hr (range 166 to 615 mg124 hr), indicating severe glomer-
ular injury (5 1 mg/24 hr in normal animals). Anti-CDI8 mAb
significantly reduced the early phase proteinuria (0 to 24 hr) by ca.
60% whereas anti-VLA-4 mAb was ineffective (Fig. 6). Combina-
tion blockade of CD18 and VLA-4 was no more effective than
anti-CD18 blockade alone in reducing proteinuria.
The decrease in proteinuria seen with mAb to CDI8 was
accompanied by a significant reduction in glomerular leukocytes
due principally to a reduction in the influx of PMNs (Fig. 7). The
decrease in PMNs with CD18 blockade was commensurate to the
decrease in proteinuria (both ca. 60%). Although mAb to VLA-4
did not effect proteinuria, a small reduction in glomerular leuko-
cyte counts was observed due to a decrease in the influx of PMNs
(Fig. 7). The combination of mAbs to CDI 8 and VLA-4, however,
were not additive. Glomerular Ms were detectible (but not
prominent) at this time point; however, their numbers were not
altered by mAb administration (Fig. 7).
Neph. aCD18 aVLA-4 aCD18+VLA-4
Fig. 9. Effect of mAbs to CDJ8 and VLA-4 on glomerular leukocytes 72
hours after induction of anti-GBM nephritis. Glomerular lcukocytcs were
measured by immunocytochemistry (Methods) 72 hours after induction of
nephritis in controls (Neph.), anti-CD18 mAb treated animals (anti-
CD18), anti-VLA-4 mAb treated animals (anti-VLA-4), and animals
treated with combination therapy (anti-CDI8+VLA-4). MAb therapy was
administered 30 minutes prior to, and 36 hours following, disease induc-
tion. Total glomerular leukocytes (A) as well as PMN (B) and M4 (C)
counts are shown. N = 12, 4, 3, and 5, respectively, for the groups as
shown. No statistically significant changes were observed.
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Effects of anti-CD18 and anti-VLA-4 inAbs on the later phase of
heterologous anti-GBM nephritis
Proteinuria persisted during the later phase of heterologous
anti-GBM nephritis as the leukocyte infiltrate became exclusively
comprised of M4s; however, the average proteinuria was still
substantial: 217 32 mg/24 hr (range 82 to 469 mg/24 hr) (Fig. 5).
In order to assess the effect of CD18 and/or VLA-4 blockade on
this phase of heterologous anti-GBM nephritis, mAbs were
readministered to animals 36 hours after disease induction based
on the aforementioned in vivo validation data (see above).
Despite a substantial attenuation of the early phase proteinuria (0
to 24 hr), continued blockade of CD18 did not attenuate the
proteinuria occurring between 48 and 72 hours after disease
induction (Fig. 8). VLA-4 blockade alone also had no significant
effect on proteinuria (Fig. 8). Combination blockade, however,
did significantly diminish proteinuria (ca. 50%) although substan-
tial proteinuria was still observed in animals treated with combi-
nation therapy (Fig. 8).
In accord with the proteinuria data, neither blockade of CDI8
nor VLA-4 altered the influx of glomerular leukocytes during the
later phase of anti-GBM nephritis which are almost exclusively
M4s (Fig. 9). Although combination blockade attenuated protein-
uria (Fig. 8), no significant effect was observed on glomerular
leukocyte influx (Fig. 9).
Effects of anti-CDI8 and anti-VLA-4 mAbs on the later phase of
heterologous anti-GBM nephritis in the absence of acute
inflammation
Because M4 migration into inflamed glomeruli has been shown
to occur independently of the influx of PMNs [19, 20], we also
addressed the effects of mAbs to CD18 and VLA-4 on the influx
of Ms into glomeruli in animals in whom the early inflammatory
phase of anti-GBM nephritis was blocked either by complement
or PMN depletion. As we have previously observed, both corn-
plement and PMN depletion completely blocked the early pro-
teinuria in this model (Fig. 10) [23, 331. This decrease in protein-
uria is due to an absence of PMN infiltration into glomeruli ([23,
33] and data not shown). Although PMN migration is abrogated
by these manipulations, M migration was not altered, although
the proteinuria which typically accompanies the influx of M4s was
completely blocked (Figs. 10 and 11). This diminished influx of
M4s could not be attributed to the lack of complement since CVF
and PMN depletion produced identical results (Figs. 10 and 11).
Because proteinuria in decomplemented animals was already
prevented, mAb administration had no further effect (Fig. 10).
However, we did observe that niAb to VLA-4, but not CD18,
significantly inhibited the influx of M4s in response to the
deposition of anti-GBM antibody by ca. 50% (Fig. 11). Addition-
ally, combining both CDI8 and VLA-4 mAbs was no more
effective than mAb to VLA-4 alone (Fig. 10). The effect of the
mAbs was identical in PMN-depleted animals (data not shown).
Discussion
The current study provides several important insights into the
mechanisms underlying the influx of leukocytes into inflamed
glomeruli during the course of glomerulonephritis. With respect
to acute inflammation, this study establishes the importance of
CD18 to PMN migration and activation in acute nephritis. As we
observed, PMN migration into inflamed glomeruli and in situ
activation were blocked ca. 60% by saturating levels of anti-CD18
mAb. This degree of inhibition, though, is intermediate relative to
other models of inflammation [14, 15], and supports the concept
that the contribution of CD18 to PMN migration/activation may
vary substantially depending on the inflammatory stimulus or
tissue involved.
The data also establish that there is a significant CD18-
independent component to these processes. The presence of such
a CD18-independent pathway may explain why anti-CD18 mAbs
have not been invariably effective in inhibiting acute nephritis
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Fig. 10. The effect of complement and PMN
depletion on proteinuria after induction of anti-
GBM nephritis. Nephritis was induced in
controls (Neph.), or animals who had been
depleted of complement or PMNs prior to
disease induction using CVF or a specific
polyclonal antiserum (aPMN). Subgroups of
decomplemented animals also received mAb to
CD18, VLA-4 or both 24 hours after disease
induction (CVF+ aCD18, CVF+ oVLA-4,
CVF+ ccCDl8+VLA-4). Proteinuria was
measured from 0 to 24 hours and from 48 to 72
.
hours and is normalized to contemporaneously
> performed controls. Average proteinuria in
o controls was 258 34 mg/24 hours (range 100
+ to 517 mg/24 hr) from 0 to 24 hours and 118
20 mg124 hours (range 40 to 252 mg/24 hr)
from 48 to 72 hours. N = 11, 18, 3, 11, 5, 3, 6,0 4, and 3 in the groups shown. The decreases in
______________________
proteinuria observed at both 0 to 24 and 48 to
72 hours in all experimental groups relative to
+CVF control were statistically significant (P < 0.001).
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Fig. 11. Effect of ,nAbs to CDJ8 and VLA-4 on glomerular leukocytes 72
hours after induction of anti-GBM nephritis after abrogation of acute
inflammation. Glomerular leukocytes were measured by immunocyto-
chemistry (Methods) 72 hours after induction of nephritis in controls
(Neph.), decomplemented animals (+CVF), PMN-depleted animals(aPMN), and decomplemented animals treated with mAbs to either
CD18, VLA-4 or both (CVF+aCD18, CVF+aVLA-4, CVF+csCDl8+
VLA-4). MAb therapy was administered 24 hours following disease
induction. Total glomerular leukocytes (A) as well as PMN (B) and M4
(C) counts are shown. N 10, 3, 3, 5, 5, and 3, respectively, for the groups
as shown. Decomplemented animals treated with anti-VLA-4 mAb (alone
or in combination) exhibited a decrease in glomerular leukocytes and Ms
relative to control (P < 0.01).
[18]. Although prior studies have suggested that CD18-indepen-
dent PMN migration/activation may involve VLA-4 [11], this
conclusion does not appear applicable to this model of nephritis.
Although this study, and a prior one [17], noted a modest effect of
VLA-4 blockade on PMN migration/activation, the current work
demonstrates that this effect is not additive to that of CD18
blockade. The nature of the CD18-independent pathway for PMN
migration/activation in this model of inflammation thus remains
to be clarified.
With respect to the later phase of heterologous anti-GBM
nephritis, the present study suggests that the in vivo migration of
m000cytes into inflamed glomeruli is more complex than what has
been observed for monocyte adherence and transendothelial
migration in vitro [7—10] and monocyte migration in vivo in other
models of inflammation [11—13]. In these cited studies, monocyte
adherence and migration appear to be largely mediated through a
cooperation between CD18 and VLA-4 [7—10]. In the present
study, however, we found that CD18 did not contribute signifi-
cantly to monocyte migration into inflamed glomeruli in vivo.
However, VLA-4 did appear to mediate a component of mono-
cyte migration into inflamed glomeruli, although its contribution
in this regard was diminished if preceded by a severe acute
inflammatory phase. With respect to monocyte/M4 activation, the
current data suggest that both VLA-4 and CD18 may make a
contribution although we cannot dissect out the individual con-
tributions of each from the current data.
The relevance of our findings to the chronic phase of anti-GBM
nephritis (which may progress to glomeruloscierosis) remains to
be clarified. Apropos to this issue, we would note that recent
studies on the evolution of chronic anti-GBM nephritis found that
CD11a/CD18 and its counterreceptor, ICAM-1, were coopera-
tively important for the development of chronic nephritis and
glomeruloscierosis, potentially via a decrease in M4 migration
and activation [21, 22]. There are several possible reasons for the
apparent difference between these studies and the current one
regarding the role of CD18 in nephritis. First, chronic nephritis
requires an active immune response (that is, antibody formation)
whereas the heterologous phase of anti-GBM nephritis is a
passive model. Second, chronic nephritis is often characterized by
the accumulation of glomerular T cells (which may be blocked by
anti-CD18 therapy), whereas in the heterologous phase of anti-
GBM nephritis lymphocytes are typically absent [34]. Third, a
contribution of PMNs to the glomerular injury in the cited studies
was not conclusively ruled out. Although CD11a/CD18 does not
appear to contribute PMN migration and activation in nephritis,
ICAM-1 does make a major contribution through its interaction
IL Z .
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with CD11b/CDI8 [17]. Fourth, M4 migration and activation in
chronic nephritis may involve distinct mechanisms from those
engaged earlier on in disease pathogenesis.
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With respect to this latter issue, we would note that while our
data demonstrate that M4 migration in heterologous anti-GBM
nephritis is PMN- and complement-independent, we found that
M4 activation (in terms of proteinuria) is not. In fact, MCI)
migration into glomeruli in heterologous anti-GBM nephritis was
not associated with proteinuria in the absence of a preceding
acute inflammatory response. In contrast, both MI) migration and
activation are PMN- and complement-independent in chronic
anti-GBM nephritis [19, 201. These observations support the
above hypothesis that the mechanisms underlying M4 migration
and activation in chronic autologous anti-GBM nephritis may
differ from those in the more acute phase of this disease model.
Regardless, we have observed that PMNs may make an important
contribution to chronic glomerular injury and glomerulosclerosis
independently of M4s [35].
In sum, the current study establishes that both CDI8 and
VLA-4 contribute to leukocyte migration and activation in heter-
ologous anti-GBM nephritis, although there are clearly important
non-CD18/VLA-4 pathways that participate in these process. The
contribution of CDI8 and VLA-4 to chronic nephritis and gb-
merular scarring, however, remain to be more clearly defined.
Further clarification of these issues may help elucidate further
how leukocyte migration/activation can be manipulated to ame-
liorate glomerular dysfunction and its long term consequence of
gbomerubosclerosis. Given the limited pharmacologic options cur-
rently available for treating immune-mediated glomerulonephritis
in humans, such studies may have potential therapeutic impact.
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